Business Context and Reporting Period
Company: Kalaris Therapeutics, Inc. (formerly AlloVir, Inc.)
Filing Date: March 18, 2025
Event: Completion of a reverse merger with Legacy Kalaris (Kalaris Tx, Inc.).
Current Status: The Combined Company is a clinical-stage biopharmaceutical firm focused on retinal diseases. The entity formerly known as AlloVir changed its name to Kalaris Therapeutics, Inc. and ceased to be a shell company. Trading commenced on the Nasdaq Global Market under the ticker KLRS on March 19, 2025.
Key Financial Metrics and Capital Structure
Capitalization Post-Merger:
- Total Shares Outstanding: Approximately 18,702,413 shares immediately following the Effective Time.
- Ownership Split: Legacy Kalaris securityholders own approximately 74.47%; pre-closing AlloVir securityholders own approximately 25.53%.
- Major Shareholder: Samsara BioCapital, L.P. beneficially owns 61.19% of the outstanding shares.
- Convertible Notes: Outstanding 2024 notes converted to common stock at $1.25/share. Outstanding 2025 notes converted to Series B-2 Preferred Stock (at $4.7851/share) and subsequently to common stock.
- AlloVir Note: A $3.75 million principal advance (part of a $7.5 million facility) issued in January 2025 was cancelled at the Effective Time.
- Cash Flow/Revenue: The filing text does not provide specific revenue, profit, or cash flow figures for the Combined Company; these are incorporated by reference in Exhibits 99.4, 99.5, and 99.6.
- Exchange Ratio: 0.2016 shares of Combined Company Common Stock for each share of Legacy Kalaris Common Stock.
- AlloVir Options: Options with exercise prices $\ge$ $92.00 were cancelled; unvested options with prices < $92.00 were accelerated in full.
Material Changes Versus Prior Period
Corporate Structure:
- Name Change: From "AlloVir, Inc." to "Kalaris Therapeutics, Inc."
- Listing: Moved from Nasdaq Capital Market (ALVR) to Nasdaq Global Market (KLRS).
- Shell Status: Transitioned from a shell company to an operating clinical-stage biopharmaceutical company.
- CEO: Andrew Oxtoby (formerly of Legacy Kalaris) appointed CEO. Vikas Sinha (former AlloVir CEO) resigned.
- Board Composition: Reconstituted with 8 directors and 1 vacancy. Legacy Kalaris representatives hold the majority of seats.
- Control: The Company is now a "controlled company" under Nasdaq rules due to Samsara BioCapital's majority ownership.
Guidance, Outlook, and Risks
Outlook:
- The Combined Company is focused on developing therapeutics for prevalent retinal diseases, specifically mentioning product candidate TH103.
- Management expects to adopt a new non-employee director compensation program following the merger.
- Capital Needs: Risk of inability to obtain sufficient additional capital to advance product candidates.
- Clinical Uncertainty: Risks associated with clinical trial delays, regulatory approval, and unexpected costs.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from projections regarding strategy, operations, and financial position.
- Legal: Potential involvement in litigation, including securities class actions.
Investor Verification Checklist
- Pro Forma Financials: Review Exhibit 99.6 for unaudited pro forma condensed combined financial information to assess the post-merger financial position.
- Audited Statements: Examine Exhibit 99.5 for Legacy Kalaris's audited financial statements for years ended Dec 31, 2024 and 2023.
- Ownership Concentration: Verify the implications of Samsara BioCapital's 61.19% ownership on corporate governance and minority shareholder rights.
- Product Pipeline: Confirm the development status and clinical trial timelines for TH103 and other retinal disease candidates.
- Debt Conversion: Validate the final share count resulting from the conversion of the 2024 and 2025 convertible notes.